Sars-CoV2 Clinical Trial
Official title:
NOsocomial Dissemination Risk of SARS-Cov2
To date, in France, in the context of the SARS Cov2 pandemic,both the number of affected subjects and the number of severe forms requiring hospital care are increasing. Several nosocomial transmission clusters have already been identified in hospitals (both pediatric and adult) but there is still limited data on the nosocomial spread of SARS-Cov2. This nosocomial transmission affects both patients and caregivers. It is important to understand the spread of the virus within the hospital. This will help to optimize procedures to prevent transmission to caregivers and hospitalizedpatients not infected with SARS Cov2, and more generally this will contribute to control the spread of SARS Cov2 in the community
It is an observational study without any risk. Every participating service will be investigated for 2 consecutive days . - At each staff rotation, an individualsensorwill be provided toall thestaff(caregivers, administrative, students etc…) to be worn duringtheirworking hours. Also a sensor will be placed at each patient's bedside. - In addition, epidemiological data relating to socio-demographic characteristics, profession, protective measures will be collectedfrom hospitalstaff. Also, some data from the 'entrepot des données de santé" regarding individual carepathways in the hospitalwill be extracted. - A map of the unit, specifying the location of each patient will be made. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04446065 -
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
|
Phase 2/Phase 3 | |
| Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
| Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
| Completed |
NCT04463004 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 | |
| Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
| Recruiting |
NCT04581148 -
SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
|
||
| Recruiting |
NCT04441372 -
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
|
||
| Completed |
NCT04530604 -
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
|
Phase 1 | |
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Active, not recruiting |
NCT04635605 -
Methylene Blue Treatment of COVID-19
|
Phase 2 | |
| Recruiting |
NCT04395599 -
Risk of Air Contamination During Visceral Surgery in COVID19 Patients
|
N/A | |
| Recruiting |
NCT04472585 -
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04411433 -
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
|
Phase 3 | |
| Completed |
NCT04359706 -
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
|
||
| Recruiting |
NCT04395794 -
SARS-CoV-2 Disguise Study
|
||
| Completed |
NCT04386551 -
Detection of COVID-19 in Saliva Collection
|
||
| Recruiting |
NCT04403269 -
NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE
|
Phase 2 | |
| Withdrawn |
NCT04379492 -
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
|
Phase 2 | |
| Completed |
NCT04379336 -
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
|
Phase 3 |